

Popularity of Personal Health Records Growing

BY MARY ELLEN SCHNEIDER
New York Bureau

As physicians struggle to decide if or when to incorporate electronic health records into their practices, personal health records are gaining popularity.

Personal health records (PHRs) allow patients to store and access their medical information electronically. Various versions are available through physicians, health systems, insurers, and employers, and are offered on a stand-alone, subscription basis. But with so many models, no two records are likely to be the same, and each may present different challenges for the physician-patient relationship.

"We're really in a kind of Wild West situation with the PHR," said Dr. Peter Basch, an internist and medical director for eHealth at MedStar Health, a seven-hospital system in Washington and Baltimore.

Currently, two types of records are dominant—those that are linked to a physician's or health system's electronic health record, and free-standing records, Dr. Basch said.

With connected PHRs, patients can usually access subsets of their medical data and communicate with their physicians' offices on selected matters such as scheduling appointments. With a free-standing PHR, patients generally have greater control of the data that are entered, and of who can access the data. The market is more mature now in terms of connected PHRs, especially those that are linked to large medical groups and large health systems, Dr. Basch said.

In an effort to tame some of the variability in the market, Health Level Seven Inc. (HL7), a national organization that sets health information technology standards, has released a proposed personal health record standard. In August, HL7 unveiled its Personal Health Record System Functional Model, and sought public comments on it. The HL7 general model can be customized so that it can be used with each of the various PHR models available in the marketplace.

Another possible way to accelerate the development of the personal health record market is through the Certification Commission for Healthcare Information Technology (CCHIT), a body that already certifies ambulatory and inpatient electronic health record systems.

The CCHIT is looking at the area of personal health records, according to its chairman, Dr. Mark Leavitt. However, any certification of PHR products would be at least a year off, since the CCHIT has not developed certification criteria in that area. Although the PHR industry is still in its early stages, it is not necessary to wait for the industry to fully mature before developing certification criteria. In fact, setting standards early can be helpful, Dr. Leavitt said.

The PHR marketplace also may get a boost from the CCHIT long before a PHR certification process gets off the ground, Dr. Leavitt added. Through its electronic health record certification process, the CCHIT is requiring that records have the capability to send patient summary infor-

mation, which would be helpful in populating a patient's PHR.

Many factors are driving the growth of PHRs. Employer groups, frustrated with escalating health costs, represent one faction pushing for PHR development.

Health insurers also are getting into the act. For example, Aetna recently announced that, starting this month, federal enrollees in any of the company's medical plans will have access to a password-protected online PHR. Even

Medicare is testing the PHR field. Even if most consumers are not clamoring for PHRs, when surveyed, they do favor the concept. For example, in a November 2006 survey commissioned by the Markle Foundation, nearly two-thirds of the 1,003 adults polled said they would like to access their medical information electronically.

But consumers who were surveyed also had significant concerns about the privacy and security of their records. For example, 80% said they were very concerned about

identity theft, and 77% said they were very concerned about their medical information being used for marketing purposes.

Concerns about security and privacy are shared by physicians. With a free-standing PHR, physicians could receive requests from patients to populate their data, but they might be reluctant to send such sensitive data in an unsecured way or in a way that could compromise the security of their own electronic systems, Dr. Basch said. ■

Relief is at your fingertips

CUTIVATE LOTION IS THE

ONE

NEW
120-mL
size

ONE daily dose
proven to get results¹

- Effective relief in a flexible QD-dosing regimen for adults and children as young as 1 year of age¹
- Nongreasy, moisturizing lotion formulated with the emollient dimethicone to help enhance skin-barrier protection and guard against irritation^{2,3}
- No evidence of HPA*-axis suppression, skin atrophy, or pigmentation changes in phase 3 clinical studies^{1,3,4}

Available in 120-mL and 60-mL sizes!



fluticasone propionate lotion

Once-daily
CUTIVATE® LOTION, 0.05%
(fluticasone propionate lotion)

The ONE for all AD severities

* HPA = hypothalamic-pituitary-adrenal.

CUTIVATE LOTION is indicated for the relief of the inflammatory and pruritic manifestations of atopic dermatitis in patients 1 year of age and older.

Not for ophthalmic, oral, or intravaginal use, or for use by patients with a hypersensitivity to any of its components. In clinical studies, drug-related side effects following the use of CUTIVATE LOTION consisted primarily of localized burning and stinging, and were usually mild and self-limiting. No skin atrophy, changes in pigmentation, or evidence of HPA-axis suppression were observed following the use of CUTIVATE LOTION in these studies. Adrenal suppression has been observed in studies with other fluticasone propionate topical formulations.

References: 1. Cutivate® [Prescribing Information]. Duluth, GA: PharmaDerm, a division of ALTANA Inc. 2007. 2. Uliasz A, Lebwohl M. Dimethicone as a protective ingredient in topical medications. Poster presented at: The 65th Annual Meeting of the American Academy of Dermatology; Feb. 2-6, 2007; Washington, DC. 3. Eichenfield LF, Miller BH, on behalf of a Cutivate Lotion Study Group. Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age. *J Am Acad Dermatol.* 2006;54:715-717. 4. Hebert AA, Friedlander SF, Allen DB, for the Fluticasone Pediatrics Safety Study Group. Topical fluticasone propionate lotion does not cause HPA axis suppression. *J Pediatr.* 2006;149:378-382.

Please see next page for Brief Summary of Prescribing Information.

 PharmaDerm®

CUTIVATE LOTION is a registered trademark of PharmaDerm, a division of ALTANA Inc. ©2007 PharmaDerm, Duluth, GA 30096. All rights reserved. 98CL690807